TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

 

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Strengthening U.S. growth reflects help from Federal Reserve
  2. Sweet tooth will cost you more next year
  3. How to avoid Amazon and still get deals
  4. Radiation detection of drilling waste nearly set at W.Va. landfills
  5. Mylan’s 3Q profit triples on strong U.S. sales
  6. Profit falls at vitamin retailer GNC Holdings in third quarter
  7. Bayer profit edges higher, raises forecasts
  8. CCAC, Energy Innovation Center respond to energy industry’s growing demand
  9. Highmark’s new REMWorks Sleep Store will sell sleep apnea equipment
  10. Hedge funds sue to block EDMC deal
  11. Apple CEO Tim Cook: ‘I’m proud to be gay’
Subscribe today! Click here for our subscription offers.